Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.06

-2.9%

Dec 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (13244)	9/30/2004 2:58:12 PM
From: scaram(o)uche	Read Replies (1) of 52153

>> This ought to be good for biotech, though. << This systems biology company can tell some companies, up-front, that their molecules will have trouble down the road. bioseekinc.com I feel that it's negligent that every pharma CEO is not beating at their front door, wanting in. I have no concept if THIS (vioxx) issue could have been predicted, but....... >> This ought to be good for biotech, though. << Both pharmacogenomic and systems biology business plans have been slow to unfold, despite the obvious utility and wisdom. systems biology became a dirty phrase, and pharmacogenomics was merely thought to be unworkable. Billions went poof. Look at the volume in October calls today, relative to outstanding interest.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next